Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dainippon Sumitomo Starts Joint Research With Osaka University

This article was originally published in PharmAsia News

Executive Summary

Dainippon Sumitomo announced Oct. 23 that the company will collaborate with Osaka University on neuroscience research. The company will establish a neuropsychiatry drug discovery consortium with five divisions of the university's medical and pharmaceutical schools. The first research phase is planned for three years, from November 2008 to October 2011, and the company plans to invest ¥300 million in the project. Osaka University has conducted gene level research and aims to develop new drugs based on the research through forming alliances with pharmaceutical companies. (Click here for more - Japanese language)

You may also be interested in...

Canadian Body Addresses Shortages Risk

The CGPA and Biosimilars Canada have acknowledged the risk of local shortages amid the coronavirus crisis, after Health Canada advised Canadians that buying more medicine than usual could lead to local supply disruptions.

Circassia Ends AZ Deal To Dig Itself Out Of Debt Hole

Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.

Regulators Insist On Large-Scale Trials For Coronavirus Treatment Candidates

At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts